Tuberculosis Treatment Drugs Market Thumbnail Image

2023

Tuberculosis Treatment Drugs Market

Tuberculosis Treatment Drugs Market Size, Share, Competitive Landscape and Trend Analysis Report by Disease Type, by Therapy Type, by Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

LS : Pharmaceuticals

Select an option
Author's: Monika Darandale | Roshan Deshmukh
Publish Date:

Get Sample to Email

Tuberculosis Treatment Drugs Market Research, 2031

The global tuberculosis treatment drugs market size was valued at $1.9 billion in 2021, and is projected to reach $3.2 billion by 2031, growing at a CAGR of 5.3% from 2022 to 2031. Tuberculosis (TB) is a bacterial infection caused by Mycobacterium tuberculosis that primarily affects the lungs but can also affect other parts of the body. It is treated with a combination of antibiotics taken over six to nine months.

First-line drugs include isoniazid, rifampicin, ethambutol, and pyrazinamide, while second-line drugs include fluoroquinolones, aminoglycosides, and capreomycin. Treatment must be completed in full, even if symptoms improve before the end of the course of antibiotics. For drug-resistant TB, newer drugs such as bedaquiline and delamanid may be used. Patients receiving TB treatment should work closely with their healthcare provider to ensure that they are taking their medication correctly and to monitor for any potential side effects. It is also important for patients to follow any additional recommendations from their healthcare provider, such as avoiding close contact with others until the infection is no longer contagious. 

Tuberculosis Treatment Drugs Market

Market Dynamics 

Growth & innovations in the pharmaceutical industry for the manufacturing of anti-TB drugs, owing to increase in the prevalence of tuberculosis, creates an tuberculosis treatment drugs market opportunity. Rise in product approvals of various anti-TB agents and increase in number of clinical trials of new drugs by various key players across the globe are set to affect the market growth positively. In addition, rising prevalence of tuberculosis cases is driving the demand for effective anti-TB drugs, thus driving the growth of the market.  

The tuberculosis treatment drugs market trends in emerging market which drive the growth of the market due to availability of improved healthcare infrastructure, increase in unmet healthcare needs, a rise in the prevalence of drug-resistant cases in adults, and surge in demand for anti-TB drugs for management of tuberculosis infection. Furthermore, the healthcare industry in emerging economies is developing at a significant rate, owing to rise in demand for enhanced healthcare services, significant investments by the government to improve healthcare infrastructure, and development of the medical tourism industry in emerging countries. Various organizations along with the government are counselling people regarding prevention and treatment available for tuberculosis.

E-commerce (electronic commerce) has become a vital tool for small and large businesses globally, due to rise in preference of consumers for online shopping over traditional purchasing methods. Various animations through health apps to educate people regarding tuberculosis infection and usage of medications have contributed toward the growth of tuberculosis treatment drugs market. The demand for effective anti-TB agents is not only limited to developed countries but is also being witnessed in the developing countries, such as China, Brazil, and India, which fuel the growth of the market. Moreover, an increase in promotional activities by manufacturers and growth in awareness for early detection and treatment for TB to reduce the risk of transmission and improve treatment outcome in the general population is expected to fuel their adoption in the near future. 

However, side effects of the anti-TB drugs restrain the growth of the tuberculosis treatment drugs market size. In addition, the absence of favorable reimbursement policies is expected to constrain the growth of the market. In contrast, rise in demand for novel  medications, increase in awareness about treatment options and increase in R&D to develop safe and efficacious drugs for tuberculosis infections offers potential boost to the market growth. Furthermore, increase in guidelines on improved treatment regimens offered by many government agencies offers lucrative opportunities to key players of the tuberculosis treatment drugs market. 

The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. The COVID-19 pandemic positively impacted the growth of the tuberculosis treatment drugs industry, owing to the rise in number of patients suffering from TB and COVID-19 infection leading to increase in coinfection cases and difficulty in diagnosis of both individually as it affected the same part of the body, such as the lungs. In addition, increase in drug resistant TB and relapse TB cases; which were slowly declining as a result of government initiative such as “End TB by 2025” had a potential impact on post-pandemic period of market. Moreover, the disruption to TB services and treatment during the pandemic, as well as the indirect impact of COVID-19 on health systems and poverty levels, have led to increases in TB cases in some areas. 

Further, increased focus on strengthening health systems and improving laboratory diagnostics, which could have positive knock-on effects on TB control efforts is potentially having a positive impact on tuberculosis treatment drugs market growth during the forecast period.  

Segmental Overview 

The global tuberculosis treatment drugs market is segmented into disease type, therapy type, distribution channel, and region. On the basis of disease type, the market is categorized into active tuberculosis and latent tuberculosis. As per therapy type, the market is categorized into first line therapy and second line therapy. According to distribution channel, the market is segregated into hospital pharmacies, drug stores, retail pharmacies, and online pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

By Disease Type: The market is categorized into active TB and latent TB. The active TB segment accounted for the largest share in 2021, owing to rise in prevalence of tuberculosis cases across the globe and rise in number of key players offering novel medications. On the other hand, and latent TB expected to witness highest CAGR during the forecast period owing to initiatives taken by government by providing guidelines for the treatment of latent tuberculosis and increased awareness of the risk associated with untreated latent tuberculosis condition.

Tuberculosis Treatment Drugs Market by Disease Type

 

By Therapy: The market is categorized into first line therapy and second line therapy. The first line therapy segment accounted for largest share in 2021 owing to increase in use of these drugs for treating tuberculosis as these drugs are highly effective and used in combination with other antibiotics for treating types of tuberculosis. On the other hand, second line therapy is expected to witness highest CAGR during the tuberculosis treatment drugs market forecast period owing to, increase in prevalence of drug resistance TB in patients.

Tuberculosis Treatment Drugs Market by Therapy Type

 

By Distribution Channel: The market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores and retail pharmacies segment occupied largest tuberculosis treatment drugs market share in 2021 and is expected to remain dominant during the forecast period owing to increase in preference of the people toward retail pharmacies, as retail pharmacies guide regarding medications and usage during treatment period. The online providers segment is projected to register the highest CAGR during the forecast period owing to the rise in popularity of online pharmacies and the number of users preferring online pharmacies.

Tuberculosis Treatment Drugs Market by Distribution Channel

 

By Region: The tuberculosis treatment drugs market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for largest tuberculosis treatment drugs market share in 2021 and is expected to remain dominant during the forecast period owing to rise in prevalence of tuberculosis cases, presence of key players offering anti-TB agents, and rise in healthcare infrastructure drive the growth of the tuberculosis treatment drugs market.

However, Asia-Pacific is anticipated to witness notable growth, owing to increase in investments for development of anti-TB agents, increase in drug resistant TB cases, and number of pipeline medications for treating tuberculosis conditions, thereby driving the growth of the market during the forecast period.  In addition, various private organizations organize educating camps for awareness of diagnosis, prevention, and treatment options available across the globe, thereby driving growth of tuberculosis treatment drugs industry. 

Tuberculosis Treatment Drugs Market by Region

   

Competition Analysis 

Competitive analysis and profiles of the major players in the tuberculosis treatment drugs market, such as Lupin, Sanofi, Pfizer Inc., Fresenius SE & Co. KGaA (Fresenius Kabi), Johnson & Johnson, Teva Pharmaceuticals, Novartis AG, ANI Pharmaceuticals Inc, Otsuka Pharmaceutical Co., Ltd., and Macleods Pharmaceuticals Ltd. are provided in this report. Major players have adopted product approval, funding, and agreement as key developmental strategies to improve the product portfolio of the tuberculosis treatment drugs market.  

Recent Approvals and Advancements in Tuberculosis Treatment Drugs Market 

  • In July 2021, ANI Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration approved Abbreviated New Drug Application (ANDA) for Rifabutin Capsules USP, 150 mg. 
  • In October 2021, Otsuka Pharmaceutical Co., Ltd., received European Commission approval for Deltyba (delamanid) 25-mg dispersible tablet formulation for the treatment of tuberculosis. 

Agreement in Tuberculosis Treatment Drugs Market 

  • In October 2022, Lupin Limited announced an agreement with Unitaid, The Aurum Institute, the Clinton Health Access Initiative (CHAI), and other global procurement agencies to support tuberculosis prevention treatment and introduction of two new fixed-dose formulations; that will be rolled out to 138 countries, including many low-and middle-income countries with a large burden of TB. 

Funding in Tuberculosis Treatment Drugs Market 

  • In August 2021, Otsuka Pharmaceutical Co., Ltd., received a grant of USD 17.8 million from the Bill & Melinda Gates Foundation to support the clinical trial of a treatment-shortening regimen in drug-sensitive tuberculosis. 

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tuberculosis treatment drugs market analysis from 2021 to 2031 to identify the prevailing tuberculosis treatment drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the tuberculosis treatment drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global tuberculosis treatment drugs market trends, key players, market segments, application areas, and market growth strategies.

Tuberculosis Treatment Drugs Market Report Highlights

Aspects Details
icon_1
Market Size By 2031

USD 3.2 billion

icon_2
Growth Rate

CAGR of 5.3%

icon_3
Forecast period

2021 - 2031

icon_4
Report Pages

322

icon_5
By Disease Type
  • Active Tuberculosis
  • Latent Tuberculosis
icon_6
By Therapy Type
  • First Line Therapy
  • Second Line Therapy
icon_7
By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers
icon_8
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, India, Rest of Asia-Pacific)
  • LAMEA  (Latin America, Middle East And Africa)
icon_9
Key Market Players

Lupin, Novartis AG, Teva Pharmaceutical Industries Ltd., Macleods Pharmaceuticals Ltd., Johnson & Johnson, ANI Pharmaceuticals, Inc., FRESENIUS SE & Co. KGaA (Fresenius Kabi), Sanofi, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc.

Analyst Review

The increase in demand for novel tuberculosis treatment drugs and rise in investments for research and development of tuberculosis treatment drugs globally is expected to offer profitable opportunities for the expansion of the market. In addition, favorable government initiatives and higher spending for tuberculosis treatment drugs, has piqued the interest of several companies to develop new and more effective TB treatment drugs. 

 Increasing burden of multi-drug resistant TB across the globe has resulted in rise in demand for novel therapeutics, thus driving the growth of market. Furthermore, North America accounted for largest share in 2021 and is expected to remain dominant during the forecast period owing to higher healthcare awareness, early detection of tuberculosis cases, and presence of trained medical professionals which drive the growth of tuberculosis treatment drugs market. However, Asia-Pacific is anticipated to witness notable growth, owing to higher prevalence of tuberculosis, and rising awareness for early detection of TB which are driving the growth of market during the forecast period.  

Author Name(s) : Monika Darandale | Roshan Deshmukh
Frequently Asked Questions?

Tuberculosis treatment drugs such as Isoniazid, Rifampin, Ethambutol, Pyrazinamide and others are used to treat the infection caused by Mycobacterium tuberculosis in lungs.

The major factor that fuels the growth of the tuberculosis tretament drugs market are rise in drug resistant -TB cases, rise in government initiatives to eleminate TB and rise in research activities related to anti-tuberculosis medications.

The active tuberculosis is the most influencing segment in tuberculosis treatment drugs market, owing to higher prevalence of tuberculosis cases across the globe and rise in number of key players offering novel medications.

Top companies such as, Macleods Pharmaceuticals Ltd, Lupin, Sanofi and Novartis AG, held a high market position in 2021. These key players held a high market postion owing to the strong geographical foothold in North America, Europe, Asia-Pacific, and LAMEA.

The base year is 2021 in tuberculosis treatment drugs market.

The market value of tuberculosis treatment drugs market in 2031 is $3,243.90 million

The forecast period for tuberculosis treatment drugs market is 2022 to 2031

The total market value of tuberculosis treatment drugs market is $1,929.96 million in 2021.

Loading Table Of Content...

Loading Research Methodology...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Tuberculosis Treatment Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021-2031